

Fondaparinux Market Analysis by Product (Branded/Generic), and Segment Forecasts to 2024

<https://marketpublishers.com/r/F448E9E261BEN.html>

Date: July 2016

Pages: 91

Price: US\$ 5,950.00 (Single User License)

ID: F448E9E261BEN

Abstracts

The global fondaparinux market is expected to reach USD 686.3 million by 2024, according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.

Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events

The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy's Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.

Further key Findings From the Study Suggest:

Generics and authorized generics of Arixtra (fondaparinux sodium) dominated the

market in 2015 with share of over 65.0%

The introduction of generic drugs in the market by Apotex, Inc., Dr. Reddy's, and Mylan N.V. is expected to drive the market growth.

Branded drug Arixtra is however anticipated to witness declining growth rate majorly owing to patent expiration, high cost, and introduction of low-cost alternatives

North America held the largest market share of the global market in 2015. Key factors attributing to the dominance include constantly increasing geriatric population, rising prevalence of thrombosis, and the introduction of low-cost generics of Fondaparinux in the U.S.

In addition, the increasing number of awareness initiatives undertaken by government and nongovernment organizations for DVT and PE is driving the growth of the market in the North American region.

China's huge population base with the rising disposable income coupled with the increased burden of chronic diseases is expected to be one of the major drivers for the Chinese market over the forecast period.

Moreover, the presence of local active pharmaceutical ingredients manufacturers and contract research organizations in China increased the number of foreign investments in the country. As a result, China is estimated to grow at CAGR of 21.2% till 2024

Major companies identified in the market include Dr. Reddy's Laboratories, Inc., GSK group of companies, Mylan N.V., and Alchemia among others.

The Fondaparinux market is a consolidated market and is marked by the presence of mergers and acquisitions

Contents

CHAPTER 1 RESEARCH METHODOLOGY

- 1.1 Research Methodology
- 1.2 Geographic Scope & Assumptions
- 1.3 Years Considered
- 1.4 List of Data Sources

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 INTRODUCTION

- 3.1 Key Findings
- 3.2 Value Chain Analysis
 - 3.2.1 Upstream
 - 3.2.2 Downstream

CHAPTER 4 MANUFACTURE

- 4.1 Manufacturing Process
- 4.2 Issues and Trends

CHAPTER 5 COST STRUCTURE

- 5.1 Bill of Material
- 5.2 Manufacturing Cost
- 5.3 Labor Cost
- 5.4 Depreciation Cost

CHAPTER 6 WORLDWIDE KEY VENDORS

- 6.1 Profile
 - 6.1.1 GlaxoSmithKline (GSK) Plc
 - 6.1.1.1 Company Overview
 - 6.1.1.2 Financial Performance
 - 6.1.1.3 Product Benchmarking
 - 6.1.1.4 Strategic Initiatives
 - 6.1.2 Alchemia Ltd.

- 6.1.2.1 Company Overview
- 6.1.2.2 Financial Performance
- 6.1.2.3 Product Benchmarking
- 6.1.2.4 Strategic Initiatives
- 6.1.3 Apotex, Inc.
 - 6.1.3.1 Company Overview
 - 6.1.3.2 Financial Performance
 - 6.1.3.3 Product Benchmarking
 - 6.1.3.4 Strategic Initiatives
- 6.1.4 Dr Reddy's Laboratories Ltd.
 - 6.1.4.1 Company Overview
 - 6.1.4.2 Financial Performance
 - 6.1.4.3 Product Benchmarking
 - 6.1.4.4 Strategic Initiatives
- 6.1.5 ScinoPharm Taiwan., Ltd.
 - 6.1.5.1 Company Overview
 - 6.1.5.2 Financial Performance
 - 6.1.5.3 Product Benchmarking
 - 6.1.5.4 Strategic Initiatives
- 6.1.6 Lupin Pharmaceuticals, Inc.
 - 6.1.6.1 Company Overview
 - 6.1.6.2 Financial Performance
 - 6.1.6.3 Product Benchmarking
 - 6.1.6.4 Strategic Initiatives
- 6.1.7 Abbott Laboratories, Inc.
 - 6.1.7.1 Company Overview
 - 6.1.7.2 Financial Performance
 - 6.1.7.3 Product Benchmarking
 - 6.1.7.4 Strategic Initiatives
- 6.2 Market Share Trends

CHAPTER 7 MARKET STATUS

- 7.1 Market Size, 2015
 - 7.1.1 Global Fondaparinux market, 2011 - 2024 (USD million)
- 7.2 Market Volume, 2015
 - 7.2.1 Global Fondaparinux market, volume, 2011 - 2024 (Thousand Units)
- 7.3 Competitive Landscape
 - 7.3.1 Heat Map

CHAPTER 8 MARKET OVERVIEW (VARIABLES, TRENDS& SCOPE)

8.1 Market Segmentation & Scope

8.2 Global Production Volume 2011 - 2016

8.2.1 Global Fondaparinux market, volume, 2011 - 2016 (thousand units)

8.3 Production Volume by Region, 2011-2016

8.3.1 North America

8.3.2 Europe

8.3.3 Asia Pacific

8.3.4 China

8.3.5 RoW

8.4 Global Production Value, 2011 - 2016

8.4.1 Global Fondaparinux market, 2011 - 2016 (USD million)

8.5 Production Value by Region, 2011 - 2016

8.5.1 North America

8.5.2 Europe

8.5.3 Asia Pacific

8.5.4 China

8.5.5 RoW

CHAPTER 9 MARKET FORECAST

9.1 Regional Market Size Forecast, 2016 to 2024

9.1.1 North America

9.1.2 Europe

9.1.3 Asia Pacific

9.1.4 China

9.1.5 RoW

9.2 Regional Consumption Forecast, 2016- 2024

9.2.1 North America

9.2.2 Europe

9.2.3 Asia Pacific

9.2.4 China

9.2.5 RoW

CHAPTER 10 MARKET DYNAMICS

10.1 Market Drivers

- 10.1.1 Expanding applications of Fondaparinux in various therapeutic areas
- 10.1.2 Expanding target audience in the Fondaparinux market
- 10.1.3 Introduction of generics in the market
- 10.2 Market Constraints
 - 10.2.1 High setup cost
- 10.3 Market Opportunities

CHAPTER 11 INVESTMENT FEASIBILITY

- 11.1 Global Economic Highlight 2015
- 11.2 Recent Developments
- 11.3 The Updated Forecast
 - 11.3.1 Advanced Economies
 - 11.3.2 Emerging Markets and Developing Economies
- 11.4 China Outlook
- 11.5 Investment in China
 - 11.5.1 Outlook on investment
 - 11.5.2 Growth opportunities
 - 11.5.3 Policy trends
 - 11.5.4 Conclusions
- 11.6 Feasibility of New Project
 - 11.6.1 Basis and presumptions
 - 11.6.2 New project

List Of Tables

LIST OF TABLES

Table 1 Death rates and severe bleeding: Fondaparinux versus low molecular weight heparin

I would like to order

Product name: Fondaparinux Market Analysis by Product (Branded/Generic), and Segment Forecasts to 2024

Product link: <https://marketpublishers.com/r/F448E9E261BEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F448E9E261BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

